Selective serotonin 3 receptor antagonist treatment for schizophrenia: Meta-analysis and systematic review

NeuroMolecular Medicine

Volumn 16, Issue 1, 2014, Pages 61-69

  Kishi, Taro ^a   Mukai, Tomohiko ^a   Matsuda, Yuki ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Granisetron; Meta analysis; Ondansetron; Schizophrenia; Serotonin 3 receptor antagonists; Tropisetron

Indexed keywords

ANTIPSYCHOTIC AGENTS; CONSTIPATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GRANISETRON; HALOPERIDOL; HUMANS; INDOLES; NAUSEA; ONDANSETRON; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SEROTONIN, 5-HT3; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; VOMITING;

EID: 84894226297     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-013-8251-0     Document Type: Article

References (28)

1. Akhondzadeh, S., Mohammadi, N., Noroozian, M., Karamghadiri, N., Ghoreishi, A., Jamshidi, A. H., et al. (2009). Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial. Schizophrenia Research, 107(2-3), 206-212.
2. Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., et al. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36(1), 71-93.
3. Chouinard, G., & Margolese, H. C. (2005). Manual for the extrapyramidal symptom rating scale (ESRS). Schizophrenia Research, 76(2-3), 247-265.
4. Cohn, L. D., & Becker, B. J. (2003). How meta-analysis increases statistical power. Psychological Methods, 8(3), 243-253.
5. Conley, R. R., & Kelly, D. L. (2001). Management of treatment resistance in schizophrenia. Biological Psychiatry, 50(11), 898-911.
6. Conley, R. R., Tamminga, C. A., Kelly, D. L., & Richardson, C. M. (1999). Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry, 46(1), 73-77.
7. DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177-188.
8. Hagan, R. M., Kilpatrick, G. J., & Tyers, M. B. (1993). Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology (Berl), 112(1 Suppl), S68-S75.
9. Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. British Medical Journal, 327(7414), 557-560.
10. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789-796.
11. Karlin, A., & Akabas, M. H. (1995). Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron, 15(6), 1231-1244.
12. Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The Positive And Negative Syndrome Scale (PANSS): Rationale and standardisation. The British journal of psychiatry. Supplement, 7, 59-67.
13. Khodaie-Ardakani, M. R., Seddighi, S., Modabbernia, A., Rezaei, F., Salehi, B., Ashrafi, M., et al. (2013). Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Journal of Psychiatric Research, 47(4), 472-478.
14. Kishi, T., Matsuda, Y., Nakamura, H., & Iwata, N. (2013a). Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials. Journal of Psychiatric Research, 47(2), 149-154.
15. Kishi, T., Meltzer, H. Y., & Iwata, N. (2013b). Augmentation of antipsychotic drug action by azapirone serotonin 1A receptor partial agonists: A meta-analysis. The international journal of neuropsychopharmacology, 16(6), 1259-1266.
16. Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet, 373(9657), 31-41.
17. Lieberman, J. A., Dunbar, G., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., et al. (2013). A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology, 38(6), 968-975.
18. Meltzer, H. Y. (1997). Treatment-resistant schizophrenia - the role of clozapine. Current Medical Research and Opinion, 14(1), 1-20.
19. Meltzer, H. Y. (2012). Serotonergic mechanisms as targets for existing and novel antipsychotics. Handbook of experimental pharmacology, 212, 87-124.
20. Meltzer, H. Y. (2013). Update on typical and atypical antipsychotic drugs. Annual Review of Medicine, 64, 393-406.
21. Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry, 17(12), 1206-1227.
22. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. British Medical Journal, 339, b2535.
23. Noroozian, M., Ghasemi, S., Hosseini, S. M., Modabbernia, A., Khodaie-Ardakani, M. R., Mirshafiee, O., et al. (2013). A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology (Berl). doi: 10.1007/s00213-013-3064-2.
24. Shiina, A., Shirayama, Y., Niitsu, T., Hashimoto, T., Yoshida, T., Hasegawa, T., et al. (2010). A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry, 9, 27.
25. Singh, S. P., Singh, V., Kar, N., & Chan, K. (2010). Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. British Journal of Psychiatry, 197(3), 174-179.
26. Wolf, H. (2000). Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scandinavian Journal of Rheumatology. Supplement, 113, 37-45.
27. Zhang, Z. J., Kang, W. H., Li, Q., Wang, X. Y., Yao, S. M., & Ma, A. Q. (2006). Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study. Schizophrenia Research, 88(1-3), 102-110.
28. Zhang, X. Y., Liu, L., Liu, S., Hong, X., da Chen, C., Xiu, M. H., et al. (2012). Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. American Journal of Psychiatry, 169(9), 974-981.